Conflicts of interest and findings of clinical trials: about rosiglitazone
| Author : Pierre Allain
||Date : 2010-4-30
We have already discussed several times in Pharmacorama about rosiglitazone, which is a subject of controversy, particularly regarding the risk of myocardial infarction.
An article in the BMJ in March 2010 compared the conclusions (favourable, neutral or unfavourable) of clinical trials concerning rosiglitazone according to authors' conflicts of interest (links with the pharmaceutical industry) and found that the most favourable opinions came from authors having conflict of interest with pharmaceutical companies.
A short paper in the BMJ shows the vagueness of the position of agencies, EMEA and MHRA about rosiglitazone and the author, Ike Iheanacho, ends by saying that the agencies must have something important to say but we do not know what